Jazz Pharmaceuticals reported second-quarter 2026 revenue of $1.21 billion, exceeding analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion at the midpoint, up from $4.38 billion and 3.6% above Wall Street expectations. Adjusted earnings per share came in at $5.71, missing the consensus estimate of $6.18 by 7.5%. Adjusted operating margin improved to 20.5% from negative 65.6% in the same quarter last year. Shares rose 2.5% to $257.97 following the announcement.
Jazz Pharmaceuticals PLCQ2 revenue beat and raised full-year guidance, though EPS missed.